Why is continuous health monitoring not a reality yet?

Waiting until cancer is already formed before acting? That approach needs to change. Science now has the tools to detect the earliest warning signs—long before a tumor even develops.

Breakthrough technologies like AI-driven monitoring and implantable sensors could transform how we detect disease, tracking subtle biological changes in real time. Instead of periodic tests that might miss critical moments, continuous screening could catch cancer in its earliest whispers—when prevention is still possible.

If we already know the steps leading to cancer, why aren't we stopping them? The answers might surprise you.

- - - -TimeStamps - - - -

00:00 Introduction
00:37 AI and Medical Advancements
02:30 Continuous Monitoring and Implantable Devices
05:52 Challenges in Funding and Implementation
10:17 Potential Solutions and Future Directions

- - - -

#aiandhealthcare #aihealthcare #cancerresearch #earlydetection #cancer

????Like, Subscribe, and Share to see more of this type of content!

— ABOUT AI AND HEALTHCARE —
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine. Discover how AI is transforming healthcare today, addressing real-world challenges and improving patient outcomes.

This series caters to anyone's listening style with bite-sized, commute-friendly insights and full-length interviews. Join co-hosts Mika Newton, CEO of xCures, and Dr. Sanjay Juneja, a globally recognized oncologist and AI thought leader at Tempus AI, as they explore cutting-edge innovations with industry pioneers.

— ABOUT DR AZRA RAZA —
Dr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York, NY. She started her research in Myelodysplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010.

Before moving to New York, Dr. Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer-reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, the British Journal of Hematology, Leukemia, and Leukemia Research. Dr. Raza serves on numerous national and international panels as a reviewer, consultant, and advisor and is the recipient of a number of awards.

— ABOUT DR SANJAY JUNEJA —
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine. Garnering over 750k followers and 20 million views on social media, Dr. Juneja’s unique ability to simplify complex topics has earned him global acclaim.

His debut podcast, Target Cancer: Podcast, amassed over 3 million downloads in more than 100 countries within just two years, setting the stage for his current AI-focused series featuring world-renowned guests. He currently serves as the VP of Clinical AI Operations at Tempus AI. https://www.linkedin.com/in/sanjayjunejamd/

Additional listening channels, at xcures.com/ai-and-healthcare

Views expressed by Dr. Juneja and guests are solely their own and are not attributable to xCures, Tempus, or any of our guests' affiliations.